Pacira Q2 2025 revenue $181.1M, GAAP net loss $4.8M; guidance updated, legal win $28.3M

Pacira BioSciences, Inc.

2025-Q2 EPS reported $0.00 revenue$350,022,000

Total revenues $181.1M (+2% YoY); EXPAREL $142.9M, ZILRETTA $31.3M, iovera° $5.6M.
GAAP net loss $4.8M ($0.11/share) vs net income $18.9M in Q2 2024; non-GAAP net income $36.0M.
Received $28.3M from favorable court ruling on EXPAREL royalty repayment from RDF in July 2025.
New $300M five-year revolving credit facility replaces prior term loan; reduces interest expense 60bps in 2026.
2025 guidance: revenue narrowed to $730M-$750M; non-GAAP gross margin raised to 78-80%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.